Platinum-based chemo shows modest benefit in bladder Ca
Chicago-Neoadjuvant platinum-based chemotherapy is associatedwith a statistically significant improvement in the overall survival ofpatients with locally advanced bladder cancer, according to the resultsof a recent meta-analysis presented at the AUA annual meeting here. However,the treatment benefit is not strong enough to support a recommendation forusing neoadjuvant chemotherapy in this setting, said Amir Sherif, MD, PhD,speaking on behalf of the Nordic Cooperative Bladder Cancer Group.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.
Justin B. Ziemba, MD, discusses clinical factors that help identify patients at increased risk for kidney stone recurrence and guide metabolic evaluation.
Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.